India has approved Pluvicto, the first radioligand therapy for advanced prostate cancer, marking a major step in precision oncology treatment.

BulletsIn

• India has introduced structured access framework for Pluvicto radioligand therapy, enabling regulated distribution across selected nuclear medicine centres and hospitals nationwide.
• Pluvicto uses Lutetium-177 targeting PSMA-positive prostate cancer cells, delivering radiation precisely while minimizing damage to surrounding healthy tissues in patients.
• Clinical studies show Pluvicto reduces disease progression risk and improves survival outcomes, offering better treatment results for patients with advanced prostate cancer.
• Radioligand therapy represents precision oncology approach combining molecular targeting and internal radiation delivery, unlike conventional chemotherapy or external beam radiation methods.
• India’s expanding nuclear medicine infrastructure, with over 250 centres, supports adoption of advanced therapies requiring strict safety handling radioactive isotopes protocols.
• Initially, Pluvicto will be available in select hospitals, imported from European manufacturing facilities, ensuring controlled rollout and monitored patient treatment outcomes.